AU2020268861B2 - Chromosome conformation markers of prostate cancer and lymphoma - Google Patents

Chromosome conformation markers of prostate cancer and lymphoma Download PDF

Info

Publication number
AU2020268861B2
AU2020268861B2 AU2020268861A AU2020268861A AU2020268861B2 AU 2020268861 B2 AU2020268861 B2 AU 2020268861B2 AU 2020268861 A AU2020268861 A AU 2020268861A AU 2020268861 A AU2020268861 A AU 2020268861A AU 2020268861 B2 AU2020268861 B2 AU 2020268861B2
Authority
AU
Australia
Prior art keywords
chromosome
obd169
interactions
obd
dlbcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020268861A
Other languages
English (en)
Other versions
AU2020268861A1 (en
Inventor
Alexandre Akoulitchev
Ewan HUNTER
Aroul Ramadass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biodynamics PLC
Original Assignee
Oxford Biodynamics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906487.2A external-priority patent/GB201906487D0/en
Priority claimed from GB201914729A external-priority patent/GB201914729D0/en
Priority claimed from GBGB2006286.5A external-priority patent/GB202006286D0/en
Application filed by Oxford Biodynamics PLC filed Critical Oxford Biodynamics PLC
Publication of AU2020268861A1 publication Critical patent/AU2020268861A1/en
Priority to AU2021286282A priority Critical patent/AU2021286282B2/en
Priority to AU2021286283A priority patent/AU2021286283B2/en
Application granted granted Critical
Publication of AU2020268861B2 publication Critical patent/AU2020268861B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10—Detection mode being characterised by the assay principle
    • C12Q2565/101—Interaction between at least two labels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2020268861A 2019-05-08 2020-05-06 Chromosome conformation markers of prostate cancer and lymphoma Active AU2020268861B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021286282A AU2021286282B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma
AU2021286283A AU2021286283B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1906487.2A GB201906487D0 (en) 2019-05-08 2019-05-08 DNA Marker
GB1906487.2 2019-05-08
GB1914729.7 2019-10-11
GB201914729A GB201914729D0 (en) 2019-10-11 2019-10-11 DNA marker
GB2006286.5 2020-04-29
GBGB2006286.5A GB202006286D0 (en) 2020-04-29 2020-04-29 DNA marker
PCT/GB2020/051105 WO2020225551A1 (en) 2019-05-08 2020-05-06 Chromosome conformation markers of prostate cancer and lymphoma

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2021286282A Division AU2021286282B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma
AU2021286283A Division AU2021286283B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma

Publications (2)

Publication Number Publication Date
AU2020268861A1 AU2020268861A1 (en) 2021-11-25
AU2020268861B2 true AU2020268861B2 (en) 2022-02-03

Family

ID=70775424

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2020268861A Active AU2020268861B2 (en) 2019-05-08 2020-05-06 Chromosome conformation markers of prostate cancer and lymphoma
AU2021286283A Active AU2021286283B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma
AU2021286282A Active AU2021286282B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021286283A Active AU2021286283B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma
AU2021286282A Active AU2021286282B2 (en) 2019-05-08 2021-12-14 Chromosome conformation markers of prostate cancer and lymphoma

Country Status (14)

Country Link
US (1) US20230049379A1 (https=)
EP (1) EP3966350A1 (https=)
JP (2) JP7617029B2 (https=)
KR (1) KR20220007132A (https=)
CN (2) CN120591403A (https=)
AU (3) AU2020268861B2 (https=)
CA (1) CA3138719A1 (https=)
GB (3) GB2626699B (https=)
IL (1) IL287597A (https=)
MY (1) MY203765A (https=)
SG (1) SG11202112221TA (https=)
TW (1) TWI873135B (https=)
WO (1) WO2020225551A1 (https=)
ZA (1) ZA202109658B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302862A (zh) * 2021-03-04 2023-01-16 英商牛津生物力學公眾有限公司 染色體交互作用標記物
WO2025215190A1 (en) * 2024-04-12 2025-10-16 Oxford BioDynamics PLC Method of typing chromosome markers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207661A1 (en) * 2015-06-24 2016-12-29 Oxford Biodynamics Limited Detection processes using sites of chromosome interaction
WO2018100381A1 (en) * 2016-12-01 2018-06-07 Oxford Biodynamics Limited Application of epigenetic chromsomal interactions in cancer diagnostics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2704625A1 (en) * 2007-11-08 2009-05-14 University Of Washington Dna microarray based identification and mapping of balanced translocation breakpoints
US10364469B2 (en) * 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207661A1 (en) * 2015-06-24 2016-12-29 Oxford Biodynamics Limited Detection processes using sites of chromosome interaction
WO2018100381A1 (en) * 2016-12-01 2018-06-07 Oxford Biodynamics Limited Application of epigenetic chromsomal interactions in cancer diagnostics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Oxford Biodynamics, ‘EpiSwitch Methodology A robust and reliable methodology for personalised medicine’, (2018). *

Also Published As

Publication number Publication date
ZA202109658B (en) 2022-08-31
GB202117415D0 (en) 2022-01-19
TWI873135B (zh) 2025-02-21
AU2021286283A1 (en) 2022-01-06
CN114008218B (zh) 2025-06-06
US20230049379A1 (en) 2023-02-16
GB2597895B (en) 2024-09-11
TW202108773A (zh) 2021-03-01
WO2020225551A1 (en) 2020-11-12
KR20220007132A (ko) 2022-01-18
GB2597895A (en) 2022-02-09
GB2626699A (en) 2024-07-31
GB2626699B (en) 2024-11-20
AU2021286283B2 (en) 2022-04-07
JP2022532108A (ja) 2022-07-13
JP2025032205A (ja) 2025-03-11
IL287597A (en) 2021-12-01
AU2021286282A1 (en) 2022-01-06
AU2020268861A1 (en) 2021-11-25
AU2021286282B2 (en) 2022-04-07
MY203765A (en) 2024-07-17
SG11202112221TA (en) 2021-12-30
CN114008218A (zh) 2022-02-01
CA3138719A1 (en) 2020-11-12
GB202406403D0 (en) 2024-06-19
CN120591403A (zh) 2025-09-05
JP7617029B2 (ja) 2025-01-17
EP3966350A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20220325348A1 (en) Biomarker signature method, and apparatus and kits therefor
AU2020207053B2 (en) Genomic profiling similarity
US20200327962A1 (en) Statistical ai for advanced deep learning and probabilistic programing in the biosciences
US20180089373A1 (en) Integrated systems and methods for automated processing and analysis of biological samples, clinical information processing and clinical trial matching
US20180119137A1 (en) Integrated systems and methods for automated processing and analysis of biological samples, clinical information processing and clinical trial matching
EP4247980A2 (en) Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment
CA3192386A1 (en) Metastasis predictor
US20220177976A1 (en) Colorectal cancer screening method and device
EP4320618A2 (en) Cell-free dna sequence data analysis method to examine nucleosome protection and chromatin accessibility
CA3167694A1 (en) Panomic genomic prevalence score
JP2025032205A (ja) 前立腺がんおよびリンパ腫の染色体コンフォメーションマーカー
US20260002208A1 (en) Chromosome interactions
EP4301874B1 (en) Chromosome interaction markers
JPWO2020225551A5 (https=)
US20250197943A1 (en) Oncogenic structural variants

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)